OBJECTIVES: Over the past two decades, the prevalence of autism spectrum disorder (ASD) has increased signifi cantly in the United States (US). This increase in prevalence has been accompanied by a corresponding increase in health care utilization and costs associated with the disorder. The purpose of this study is to describe hospitalization and associated costs among children with ASD in the US. METHODS: For the purpose of the study, the 2006 Healthcare Cost and Utilization Project (HCUP) Kids' Inpatient Database (KID) was used. The 2006 KID contains outcome data for 3.1 million discharges from 3739 community, non-rehabilitation hospitals spread across 38 states. All hospitalizations where the primary diagnosis (ICD-9-CM) code was listed as 299.XX were categorized as autism-related. Descriptive analyses were performed and results were reported by demographic categories. Costs associated with hospitalizations were based on total charges. RESULTS: Of the 3,131,324 pediatric discharges listed in 2006 HCUP KID, 1,456 were autism-related. The total charge for these hospitalizations was $56,936,591. The average charge per autism-related hospitalization was $24,042. The average age of children with autism-related hospitalization was 12 years ( 4 years), and the average length of stay was 13 days. In terms of demographic distribution, a majority of the children were white (69%) and male (82.3%). Medicaid was listed as the primary payer for roughly half (49%) of the discharges, with private payer including HMO providing for 42.9%. For approximately 57% of the discharges, the DRG listed was for psychoses, with another 42% for organic disturbances and mental retardation. CONCLUSIONS: Autism-related hospitalizations result in signifi cant economic impact on the society. Consistent with the prevalence patterns of autism, a majority of hospitalizations occurred among males. Further research is needed to understand the factors associated with hospitalizations among children with ASD.
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PREDICTORS OF HIGHER HEALTH CARE EXPENDITURES IN PATIENTS WITH ATTENTION-DEFICIT HYPERACTIVITY DISORDER
Christensen L 1 , Sasane R 2 , Hodgkins P 2 , Harley C 3 1 i3 Innovus, Ann Arbor, MI, USA, 2 Shire Pharmaceuticals, Wayne, PA, USA, 3 i3 Innovus, Eden Prairie, MN, USA OBJECTIVES: To identify risk factors associated with higher health care costs among US commercial health plan enrollees with attention-defi cit hyperactivity disorder (ADHD). METHODS: This retrospective study used claims data from July 1, 2003 -September 30, 2007 to examine total health care costs for subjects aged 6, diagnosed with ADHD, on their fi rst prescription fi ll (index) date for an FDA-approved ADHD medication. Total cost (health plan plus patient paid amounts) included medical, pharmacy, outpatient, offi ce visits, emergency and other medical costs. Subjects had an ADHD diagnosis between January 1, 2004-September 30, 2006, and fi lled 1 prescription for an ADHD medication during the study period. Multivariate analysis was conducted for subjects with available race/ethnicity and household income data (N 38,061) . RESULTS: The highest household income group ($100,000 or more) was associated with signifi cantly higher health care cost compared with the lowest income group ( $00) (p 0.004). Follow-up costs were higher with increasing number of baseline medications (p 0.0001), additional mental health diagnoses (p 0.0001), and when the index prescriber was a neurologist, psychiatrist or internal medicine specialist, rather than a family physician (all p 0.05). Greater medication compliance (MPR 0.8) was associated with higher total costs than lower compliance (MPR 0.8) (p 0.0001). Augmentation with a drug of another class (stimulant/nonstimulant) and use of a nonstimulant or extended release amphetamine (vs. long-acting methylphenidate) as index therapy were also associated with higher cost (all p 0.05). Costs were not statistically different between males and females aged 6-12 but were higher for females and males aged 13-17 and 18 than females aged 6-12 (all p 0.0001). Race/ethnicity was not signifi cantly related to cost when controlling for demographic, baseline medical and treatment characteristics. CONCLUSIONS: The main predictors of higher health care costs for patients with ADHD were higher income, older age and factors suggesting more complicated disease or more comorbid conditions. A retrospective analysis was performed using DATASUS (Government Healthcare database) from Jan 1998 until Dec 2007 to investigate the number of hospitalizations and days of hospitalization associated with schizophrenia and the cost associated to these hospital stays. Costs are reported in Brazilian reais RESULTS: In ten years, the amount of hospitalizations due to schizophrenia reduced in 55% and the total costs associated to hospitalization reduced in 68%. The cost of one day hospitalization was R$21.12 in 1998 and R$31, 78 in 2007. The average length of stay increased 28% and the average total cost of hospitalization increased 93% CONCLUSIONS: This analysis suggests that the mental health policy was effective in reducing schizophrenia hospitalization rates and total costs and that the patients that are hospitalized are probably those with more severe condition, requiring longer stay and more expensive health care resources.
PMH77 IMPACT OF THE BRAZILIAN PUBLIC MENTAL HEALTH POLICY ON
PMH78 HOSPITALIZATION RATES AMONG INDIVIDUALS WITH BIPOLAR DISORDER INITIATING THERAPY WITH ARIPIPRAZOLE OR QUETIAPINE
Hassan M 1 , Lage MJ 2 1 AstraZeneca, Wilmington, DE, USA, 2 HealthMetrics Outcomes Research, LLC, Groton, CT, USA OBJECTIVES: Changes in rates of hospitalization were compared for patients with bipolar disorder initiating treatment with aripiprazole (ARI) or quetiapine (QTP). METHODS: Claims data for patients diagnosed with bipolar disorder from a commercial managed care database (PharMetrics January 1, 2000-December 31, 2006) were examined (N 2573). Patients were aged 18 to 64 years, initiated therapy with ARI or QTP, prescribed no other antipsychotic in the fi rst month post-initiation, had no dementia or schizophrenia diagnoses, and were continuously insured from 12 months prior through 12 months post-initiation. Patient characteristics were compared between groups using descriptive statistics. Rates of hospitalization for any cause or related to mental health or bipolar disorder, from 12 months before to 12 months after treatment initiation, were compared between groups using McNemar's test. RESULTS: Approximately 75% of patients were initiated on QTP and 25% on ARI. During the pre-initiation period, treatment groups were not signifi cantly different in terms of age, gender, or Charlson Comorbidity score, but the QTP group had a greater total number of ICD-9 coded medical diagnoses than patients in the ARI group (mean 13.11 [QTP] Many patients with depression are not responsive to fi rst-line treatment and undergo treatment switches and optimizations to discover a benefi cial regimen ('treatment-resistant' depression [TRD] ). In addition to the patient burden, TRD is associated with signifi cant economic costs. Challenges in treating patients with TRD are further complicated by the lack of a recognized defi nition of TRD. Using administrative data, we compare three claims-based methods (developed by Corey-Lisle, Crown and Russell) and a clinically-derived measure (MGH scale) of fi nding patients with TRD. METHODS: A retrospective study of patients aged 18-64 years with at least one antidepressant claim and employer-based coverage via large US fi rms. Patients had at least 2 years of continuous medical and prescription coverage in the MarketScan Database for 2000-2006 (n 106,139) . TRD classifi cation methods were replicated over a 24-month observation period. Kappa coeffi cients were used to assess agreement between dichotomous TRD measures. The relationship between continuous measures of TRD (based on the number of antidepressant switches and optimizations, and other metrics) and annual medical costs were also assessed. RESULTS: Over two thirds of patients (69.6%, n 73,872) were classifi ed in a similar manner across all four methods: 10.7 % of patients (n 11,349) were found to have TRD, and the majority of patients (58.9%, n 62,515) did not have TRD. However, 30.4% of patients (n 32,252) were classifi ed differently depending on the method. Kappa coeffi cients between pairs of methods ranged from 0.85% to 0.42%. As TRD severity increased, cost increased in an almost linear fashion. CONCLUSIONS: While patients with complex TRD are relatively easy to identify in health care administrative data, those with less complex TRD represent an opportunity for earlier recognition and intervention and associated potential cost savings. Dichotomous defi nitions of TRD may not be adequate; a gradient from moderate to complex TRD may be more useful for providers and insurers.
